Editorial: “being normal weight each day keeps NAFLD and fibrosis away”—the importance of reducing cumulative exposure to overweight. Authors' reply
Alimentary Pharmacology & Therapeutics · 2023
DOI: 10.1111/apt.17478 ↗At a glance
Editorial in Alimentary Pharmacology & Therapeutics, 2023. Written by Veeral Ajmera. Institution: NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease. 7 references. Funded by: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (original language)
LINKED CONTENT This article is linked to Ajmera et al papers. To view these articles, visit https://doi.org/10.1111/apt.17452 and https://doi.org/10.1111/apt.17460 .
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- NAFLD Research Center, Division of Gastroenterology, University of California at San Diego, La Jolla, California, USA.
- Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
ORCID profiles: Veeral Ajmera
Funding
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Cite
APA
Ajmera, V. (2023). Editorial: “being normal weight each day keeps NAFLD and fibrosis away”—the importance of reducing cumulative exposure to overweight. Authors' reply. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17478
Vancouver
Ajmera V. Editorial: “being normal weight each day keeps NAFLD and fibrosis away”—the importance of reducing cumulative exposure to overweight. Authors' reply. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17478
BibTeX
@article{Ajmera2023,
author = {Ajmera, Veeral},
title = {Editorial: “being normal weight each day keeps NAFLD and fibrosis away”—the importance of reducing cumulative exposure to overweight. Authors' reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2023},
doi = {10.1111/apt.17478}
}
EUVIMED